American Society of Hematology

Fig. 1.

$Fig. 1. A-LAK cytotoxicity toward BW variants transfected with B7-1 or B7-2. AKR-derived LAK cells were generated in the presence of IL-2 alone or in combination with IL-12 and the cytolytic activity of the respective adherent fractions was tested against BW T-lymphoma variants and the NK-sensitive tumor YAC-1. The results are represented as the mean cytolysis of the respective targets as percent specific release (±SD). (A) Sensitivity of BW-LiDhigh (×), BW-LiDhigh (B7-1) (+), BW-LiDhigh (B7-2) (▴), and YAC-1 (*) to IL-2 versus IL-2/IL-12 A-LAK effector cells. (B) Sensitivity of BW-Li (▪), BW-Li(B7-1) (⧫), BW-Li(B7-2) (•), and YAC-1 (*) to IL-2 versus IL-2/IL-12 A-LAK effector cells. Spontaneous release in all assays was less than 15%. Both experiments were performed in triplicate and repeated at least five times, giving similar results from which one is shown. Standard deviations less than ±3% are not shown for the sake of clarity.$

A-LAK cytotoxicity toward BW variants transfected with B7-1 or B7-2. AKR-derived LAK cells were generated in the presence of IL-2 alone or in combination with IL-12 and the cytolytic activity of the respective adherent fractions was tested against BW T-lymphoma variants and the NK-sensitive tumor YAC-1. The results are represented as the mean cytolysis of the respective targets as percent specific release (±SD). (A) Sensitivity of BW-LiD^high (×), BW-LiD^high (B7-1) (+), BW-LiD^high (B7-2) (▴), and YAC-1 (*) to IL-2 versus IL-2/IL-12 A-LAK effector cells. (B) Sensitivity of BW-Li (▪), BW-Li(B7-1) (⧫), BW-Li(B7-2) (•), and YAC-1 (*) to IL-2 versus IL-2/IL-12 A-LAK effector cells. Spontaneous release in all assays was less than 15%. Both experiments were performed in triplicate and repeated at least five times, giving similar results from which one is shown. Standard deviations less than ±3% are not shown for the sake of clarity.

This Feature Is Available To Subscribers Only